ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...

Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead (ARWR) offers platform diversification with clear long-term ...

Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps ... on the large collaboration deal announced with Sarepta (SRPT) (SPRT) and implications for its own ...

NexImmune has higher earnings, but lower revenue than Sarepta Therapeutics. NexImmune is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date”) that were ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date”) that were previously ...

Sarepta Therapeutics, Inc. has a 52-week low of $78.67 and a 52-week high of $173.25. The stock has a market capitalization of $12.74 billion, a price-to-earnings ratio of 106.67 and a beta of 0.81.